Daily Pharmacy News

Get your free subscription started now. Just enter your email address below.

Ensovibep in Adults Hospitalized With COVID-19

A trial of the designed ankyrin repeat protein ensovibep was terminated early for futility after clinical outcomes were not improved in hospitalized participants with COVID-19, researchers report. The engineered protein, previously designated as MP0420, was used in addition to remdesivir and other standard care. The primary outcome was time to sustained recovery through day 90 (defined as 14 consecutive days at home or place of usual residence after hospital discharge), and a composite safety outcome of death, serious adverse events, end-organ disease, and serious infections was assessed through day 90. After 485 participants had been randomized to ensovibep or placebo infusions, pulmonary outcomes, sustained recovery, and the primary composite safety outcome were not significantly different between the groups. The authors note that these results differ from the positive findings of the EMPATHY study of ambulatory patients with symptomatic COVID-19 presented earlier this year. “Taken together with the reported result from the EMPATHY trial, our findings suggest that ensovibep treatment in COVID-19 may be effective at preventing progression rather than treating severe disease in patients with a shorter duration of symptoms,” the group concludes.